Frontlight ResearchEarly access
WithdrawnNo phase
Analysis of Cardiac Biomarker Racial Discrepancies
Key facts
- Who runs it
- Methodist Health System
- Where
- Dallas, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- 15 Sept 2021
- Expected to end
- 15 Sept 2028
- Type of study
- Observational, 2 groups
- Record updated
- 4 August 2026
- Why it stopped
- PI no longer with the site
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- >18 years
- Self-identified as AA
- Self-identified as Caucasian
- NYHA class II-IV symptoms
- Left ventricle EF <40%
- First admission for HFrEF
- No echocardiography during initial admission
Who cannot take part
- Patients not meeting inclusion criteria
Where in United States
- Methodist Dallas Medical CenterDallas, United States
About the trial
What the trial wants to find out
The goal is to review cardiac biomarkers present on admission between African American patients with new onset Heart Failure compared to a comparable cohort of Caucasian patients to establish whether there is a clinically significant difference between the two groups regarding cardiac biomarker levels and initial Heart Failure severity.
Read full original descriptionShow less
Hypothesis: Cardiac biomarker levels in African American patients with new onset Heart Failure with Reduced Ejection Fraction will be significantly lower than a Caucasian cohort with new onset Heart Failure with Reduced Ejection Fraction.
The 2 groups in the trial
- New onset HFrEF AA patients
- New onset HFrEF Caucasian patients
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Analysis of Cardiac Biomarker Racial Discrepancies in African American Patients With Heart Failure With Reduced Ejection Fraction
- Record updated
- 4 August 2026